Krystal Biotech

KRYS

Last Price
04/24/26, 09:30 AM
 EDT
$
272.52
(
1.7
%)
(
+
1.7
%)
Margin of Safety
+
-45.6
%
Modeled Fair Value
$
148.28
Modeled Fair Value
$4.499 billion
Allocation Group
Current Compounder
Allocation Tier
Coming soon!

Investment Thesis

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
An icon graphic of Gouldy the Finch.
#protectYourAssets

Solt DB will launch asset deep dives for all companies in the coverage ecosystem by the end of 2026. These will seamlessly integrate into company-specific financial models, allowing members to determine a company's fair value when specific assets are included or excluded.

Want me to prioritize a specific company or asset? Let me know on Discord or through the contact page.

Last Refined

June 18, 2025
The current model INCLUDES the following assets and assumptions:
The current model is based on operating metrics, including:
  • Component A: Full-year 2025 revenue of $385.683 million and net income of $155.538 million.
The current model EXCLUDES the following assets:
  • KB105 in lamellar ichthyosis (phase 1/2)
  • KB407 in cystic fibrosis (phase 1/2)
  • KB408 in alpha-1 antitrypsin (A1AT) deficiency (phase 1/2)
  • KB707 in solid tumors of the lung (phase 1/2)
  • KB803 in ocular complications of dystrophic epidermolysis bullosa (DEB) (phase 3, label expansion for Vjuvek)
  • KB801 in neurotrophic keratitis (phase 1/2)

SEC Filings